Cancer Studies

Professor Karen Brown

• Preclinical and early clinical development of novel cancer chemopreventive agents

• Identification and development of novel biomarkers of cancer risk, prognosis and chemopreventive/chemotherapeutic agent efficacy

Professor Don J. L. Jones

• Translation of candidate biomarkers to clinical use.

• Use of high resolution LC-MS in the discovery and verification of biomarkers.

• Investigation of protein quantification using Ion mobility.

• Translation of candidate biomarkers to clinical use.

• Use of high resolution LC-MS in the discovery and verification of biomarkers.

• Investigation of protein quantification using Ion mobility.

Dr Alessandro Rufini

• Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol

• Investigating and exploiting metabolic vulnerabilities in carcinogenesis

• Using circulating cell-free DNA for early detection of cancer

Professor Anne Thomas

• The design and delivery of early phase clinical studies including chemoprevention strategies

• Improving information exchange in oncology consultations

Dr Cristina Tufarelli 

• Determine which repetitive elements are active in precancerous and cancerous cells

• Understanding what causes activation of repetitive elements

• Establish activation of which repetitive elements plays functional roles in cancer

• Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy

Professor Martin Dyer

• Molecular cytogenetics of lymphoid malignancies

• Antibody therapy of lymphoid malignancies

• Development and assessment of novel agents for therapy of B-cell malignancies   

Professor Jacqui Shaw

• Analysis of circulating cancer biomarkers through liquid biopsy

• Molecular approaches to aid early detection of cancer

• Molecular mechanisms of resistance to targeted therapy

Dr David Guttery

• Analysis of circulating cancer biomarkers through liquid biopsy

• Molecular approaches to aid early detection of cancer

• Molecular mechanisms of resistance to targeted therapy

• Utility of artificial intelligence for early detection and improving therapy stratification

Dr Esther Moss

• Analysis of circulating endometrial cancer biomarkers through liquid biopsy

• Robotic surgery for management of endometrial cancer

• Patient-initiated follow up for low-risk endometrial cancer

• Use of ex-vivo models for personalising therapies

Dr Alessandro Rufini

• Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol

• Investigating and exploiting metabolic vulnerabilities in carcinogenesis

• Using circulating cell-free DNA for early detection of cancer

Professor Martin Dyer

• Molecular cytogenetics of lymphoid malignancies

• Antibody therapy of lymphoid malignancies

• Development and assessment of novel agents for therapy of B-cell malignancies

Dr Harriet Walter

• Delivery of Phase I portfolio across haematological malignancies and solid tumours

• Therapeutic drug development

• Development and assessment of novel agents in the treatment of B-cell malignancies

Dr Matt Ahearne

• Developing new diagnostic and therapeutic approaches in T-cell lymphoma

• Targeting the microenvironment in B-cell lymphoma

Professor Jacqui Shaw

• Analysis of circulating cancer biomarkers through liquid biopsy

• Molecular approaches to aid early detection of cancer

• Molecular mechanisms of resistance to targeted therapy 

Dr David Guttery

• Analysis of circulating cancer biomarkers through liquid biopsy

• Molecular approaches to aid early detection of cancer

• Molecular mechanisms of resistance to targeted therapy

• Utility of artificial intelligence for early detection and improving therapy stratification

Professor Martin Dyer

• Molecular cytogenetics of lymphoid malignancies

• Antibody therapy of lymphoid malignancies

• Development and assessment of novel agents for therapy of B-cell malignancies

Professor Don J. L. Jones

• Translation of candidate biomarkers to clinical use.

• Use of high resolution LC-MS in the discovery and verification of biomarkers.

• Investigation of protein quantification using Ion mobility.

• Translation of candidate biomarkers to clinical use.

• Use of high resolution LC-MS in the discovery and verification of biomarkers.

• Investigation of protein quantification using Ion mobility.

Professor Bruno Morgan

• Imaging applications to monitor drug therapy

• Imaging in cancer research trials including CT, MRI, Ultrasound and PET-CT

Professor Dean Fennell

• Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers

Dr Tim Rattay

• Personalising breast cancer treatment according to predicted toxicity
• Radiogenomics and biomarkers
• Breast surgery and reconstuction
• Patients' views on breast cancer treatment and predictive testing

Professor Anne Thomas

• The design and delivery of early phase clinical studies including chemoprevention strategies

• Improving information exchange in oncology consultations

Dr Harriet Walter

• Delivery of Phase I portfolio across haematological malignancies and solid tumour
• Therapeutic drug development
• Development and assessment of novel agents in the treatment of B-cell malignancies

 Professor Martin Dyer

• Molecular cytogenetics of lymphoid malignancies

• Antibody therapy of lymphoid malignancies

• Development and assessment of novel agents for therapy of B-cell malignancies

Professor Anne Thomas

• The design and delivery of early phase clinical studies including chemoprevention strategies

• Improving information exchange in oncology consultations

Professor Catrin Pritchard

• Mechanisms of RAS/RAF oncogene induced tumour development

• RAF/MAPK signalling in normal and cancer cells

• Ex vivo patient relevant drug testing platforms

Dr Esther Moss

• Analysis of circulating endometrial cancer biomarkers through liquid biopsy

• Molecular profiling for improved stratification to immunotherapies

• Robotic surgery for management of endometrial cancer

• Patient-initiated follow up for low-risk endometrial cancer

• Use of ex-vivo models for personalising therapies

Dr Alessandro Rufini

• Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol

• Investigating and exploiting metabolic vulnerabilities in carcinogenesis

• Using circulating cell-free DNA for early detection of cancer

Dr Cristina Tufarelli

• Determine which repetitive elements are active in precancerous and cancerous cells

• Understanding what causes activation of repetitive elements

• Establish activation of which repetitive elements plays functional roles in cancer

• Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy